D
Janux Therapeutics, Inc. JANX
$17.11 $1.257.88% NASDAQ
Recommendation
Prev Close
$15.86
Volume
5,679,322
Avg Vol (90D)
1,129,574
Market Cap
$953.94M
Dividend & Yield
--
52-Week Range
$15.77 - $71.71
P/E (TTM)
--
EPS (TTM)
-$1.68
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Janux Therapeutics (JANX) Is Down 50.7% After Positive JANX007 Phase 1 mCRPC Update - What's Changed
12/3/2025 - Simply Wall St
Janux Therapeutics Sees Unusually Large Options Volume (NASDAQ:JANX)
12/3/2025 - MarketBeat
Janux Therapeutics (JANX, $15.86) price may climb as it broke lower Bollinger Band on Dec 02, 2025
12/3/2025 - Tickeron - Stocks
Janux Therapeutics (JANX, $15.86) entered Downtrend as Momentum indicator drops below 0 level on Dec 02, 2025
12/3/2025 - Tickeron - Stocks
Janux Therapeutics (JANX, $15.86) RSI Indicator left the oversold zone on December 02, 2025
12/3/2025 - Tickeron - Stocks
Janux Therapeutics (JANX, $15.86) price exceeded its 50-day Moving Average on December 02, 2025
12/3/2025 - Tickeron - Stocks
Janux Therapeutics (JANX, $15.86) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 2, 2025
12/3/2025 - Tickeron - Stocks
Janux Therapeutics (NASDAQ:JANX) Sets New 1-Year Low After Analyst Downgrade
12/3/2025 - MarketBeat
Janux Therapeutics: Downgrading To "Hold" Rating After Latest Updated Phase 1 JANX007 mCRPC Data
12/3/2025 - SeekingAlpha
Bank of America Issues Pessimistic Forecast for Janux Therapeutics (NASDAQ:JANX) Stock Price
12/3/2025 - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Given New $150.00 Price Target at Cantor Fitzgerald
12/3/2025 - MarketBeat
Janux Therapeutics Inc Clinical Data Update Transcript
12/2/2025 - GuruFocus
Noteworthy Tuesday Option Activity: SCHL, XPO, JANX
12/2/2025 - Stock Options Channel
Janux Therapeutics (JANX) Sees Significant Decline in Share Value
12/2/2025 - GuruFocus
Janux Therapeutics Enters Oversold Territory (JANX)
12/2/2025 - Nasdaq News: Markets
Janux Therapeutics falls -48.4%
12/2/2025 - The Fly
Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street Retail Sees A FOMO-Fueled Rebound
12/2/2025 - Stocktwits News Feed
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low Following Analyst Downgrade
12/2/2025 - Ticker Report
Janux Therapeutics (JANX) Experiences Significant Stock Price Decline
12/2/2025 - GuruFocus
Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'?
12/2/2025 - Yahoo! Finance: News
Janux Therapeutics falls -49.4%
12/2/2025 - The Fly
Bank of America Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price
12/2/2025 - Ticker Report
Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12/2/2025 - Benzinga
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Pfizer (PFE) and Janux Therapeutics Inc (JANX)
12/2/2025 - TipRanks Financial Blog
Janux Therapeutics price target lowered by $50 at Cantor Fitzgerald, here's why
12/2/2025 - The Fly
Income Statement
Total Revenue (TTM)
$10.00M
EBITDA (TTM)
-$142.22M
EBIT (TTM)
-$144.29M
Net Income (TTM)
-$101.90M
Balance Sheet
Total Assets (Q)
$1.02B
Total Debt (Q)
$22.66M
Total Liabilities (Q)
$48.21M
Book Value Per Share (Q)
$16.24
Cash Flow
Cash from Operations (TTM)
-$70.42M
Cash from Investing (TTM)
-$296.60M
Cash from Financing (TTM)
$388.65M
Net Change in Cash (TTM)
$21.64M
Filings
Filing Date
Thursday, November 6, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.45
7-Day Total Return
-40.59%
30-Day Total Return
-36.23%
60-Day Total Return
-28.05%
90-Day Total Return
-33.03%
Year to Date Total Return
-67.86%
1-Year Total Return
-71.42%
2-Year Total Return
85.57%
3-Year Total Return
26.74%
5-Year Total Return
--
52-week Low
Dec 02, 2025 - $15.77
52-week High
Dec 05, 2024 - $71.71
Valuation
Market Cap
$953.94M - Small Cap
Enterprise Value
-$12.39M
Price/Sales (TTM)
98.39
Price/Book (Q)
0.98
Dividends and Shares
Shares Outstanding
62.02
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.januxrx.com
Phone Number
858 751 4493
Address
10955 Vista Sorrento Parkway
San Diego, CA 92130
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr)... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed